The fact remains that the Phylomer "platform" is vastly broader than simply a screening base for endosome penetration peptides.
While the technology is hugely valuable, if PYC can arrange a commercial deal, it would be best to "spin off" this technology in a separate business unit and continuing on to apply the Phylomer technologies to other (diverse) problems.
PYC has a number of "short game" options:
- Immunology
- Cell Apotosis
- Endosomal Escape Trap
There are also a large number of "long game" opportunities.
This "snowball" could roll down hill for a very long time (to reference WB).
going intracellular, page-2
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
-0.010(7.69%) |
Mkt cap ! $559.9M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.0¢ | 11.5¢ | $308.5K | 2.533M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 358350 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 371822 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| PYC (ASX) Chart |